- Novo Nordisk will invest €2.1bn starting in 2023 to expand API production in Hillerød, Denmark.
- The new 65,000m2 facility will be operational by early 2029.
- The project will create 340 new jobs upon completion.
- The facility aims to reduce water consumption by over 40% and energy use by more than one-third.
Investment Overview
Novo Nordisk announced a €2.1bn investment starting in 2023 to expand its Active Pharmaceutical Ingredient (API) production facility in Hillerød, Denmark. This expansion aims to support the company's future portfolio in treating serious chronic diseases.
Facility Expansion
The new facility will cover approximately 65,000m2 and is designed as a multi-product site with maximum flexibility to accommodate new processes. It will feature state-of-the-art technology and a high-quality working environment. The construction will focus on efficiency and environmental sustainability, aiming to reduce water consumption by over 40% and energy use by more than one-third compared to similar API processes in other facilities.
Timeline and Job Creation
Construction is already underway, and the facility is expected to start producing API by early 2029. The project is anticipated to create 340 new jobs once the construction is completed and the facility is fully operational.
Strategic Importance
This investment underscores Hillerød and Denmark's significance in Novo Nordisk's global operations. It will enhance the company's production capacity and ability to meet future market demands, playing a crucial role in developing its late-phase clinical product portfolio.
